secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001213900-23-036402
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q1 net loss $6.5M; cash $51M; advances DN-TNF and INKmune trials
---------------------------------------------------------------------------

- Net loss $6.5M vs $6.9M YoY; R&D $4.1M, G&A $2.3M.
- Cash and equivalents $51.0M at March 31, 2023; 17.9M shares outstanding.
- FDA provides clear pathway to lift clinical hold on AD Phase 2 by year-end.
- IND filed for INKmune in mCRPC; Phase 1 in MDS/AML enrolling at three sites.
- Top-line XPro Alzheimer's results expected 2H 2024; NIH-funded depression trial pending FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/0001213900-23-036402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/ea177977-8k_inmunebio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-036402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer